Evidence-Based Complementary and Alternative Medicine

Review Article

Immunoregulation of Shenqi Fuzheng Injection Combined with Chemotherapy in Cancer Patients: A Systematic Review and Meta-Analysis

Table 1

Characteristics and quality of patients in included studies.


Study	N (T/C)	Gender (M/F)	Age (years)	Cancer type	Chemotherapy (T&C)	SQI invention (T)	Course	Indicator	Jadad score

Ren 2015 [16]	42/42	T: 24/18;	T: 61.57 ± 5.69;	NSCLC	PP	250 mL, ivgtt, qd, 10d	21d	①②③⑥	2
		C: 25/17	C: 62.53 ± 6.21
Ren 2014 [20]	65/72	T: 43/22;	T: 66.5 ± 15.3;	NSCLC	TP	50 mL, ivgtt, qd, 24d	21d	②③④⑤	2
		C: 46/26	C: 65.9 ± 14.7
Wang and Dou 2014 [19]	41/41	T: 31/10;	T: 56.1 ± 4.6;	NSCLC	NP	250 mL, ivgtt, qd, 14d	21d	①③④⑤⑥	2
		C: 29/12	C: 55.7 ± 5.1
Shan et al. 2014 [21]	40/40	T: 18/22;	T: 58.4 ± 2.1;	NSCLC	DP	250 mL, ivgtt, qd, 14d	21d	①②③④⑤⑥	2
		C: 26/14	C: 58.4 ± 2.1
Yuan 2014 [18]	35/34	N	N	NSCLC	TP	250 mL, ivgtt, qd, 24d	21d	③④⑤⑥	3
Zhao 2014 [17]	51/51	T: 33/18;	T: 65.08 ± 6.53;	NSCLC	GP	250 mL, ivgtt, qd, 24d	21d	①②	2
		C: 29/22	C: 64.72 ± 6.43
Wang et al. 2013 [22]	28/28	T: 16/12;	T: 59.14 ± 8.16;	SCLC	DP	250 mL, ivgtt, qd, 14d	21d	①③④⑥	2
		C: 18/10	C: 54.17 ± 9.23
Li 2012 [24]	25/25	N	55	NSCLC	GP	250 mL, ivgtt, qd, 10d	10d	①	2
Ao et al. 2012 [26]	30/25	N	56	NSCLC	TP	250 mL, ivgtt, qd, 24d	21d	②③④⑤⑥	3
Qiao 2012 [23]	30/30	36/24	61.2	NSCLC	TP	50 mL, ivgtt, qd, 24d	21d	①	2
Ding and Yang 2012 [25]	35/35	T: 20/15;	56.7	NSCLC	TP	250 mL, ivgtt, qd, 21d	21d	①②③④⑤⑥	2
		C: 22/13
Liu and Ren 2011 [27]	50/50	51/49	57.1	NSCLC	Taxotere & Cisplatin	250 mL, ivgtt, qd, 14d	21d	②③④⑤	2
Liu 2011 [28]	27/27	36/18	62	NSCLC	TP	60 mL, ivgtt, qd, 24d	21d	①	2
Wang 2009 [29]	36/38	T: 23/13;	N	SCLC	DP	250 mL, ivgtt, qd, 28d	21d	①②③⑥	2
		C: 22/16
Sun et al. 2007 [31]	34/28	T: 21/13;	T: 58;	NSCLC	TP	250 mL, ivgtt, qd, 21d	21d	②③④⑤⑥	2
		C: 20/8	C: 56.5
Lin and Li 2007 [32]	120/120	N	N	NSCLC	NP/TP	250 mL, ivgtt, qd, 14d	28d	①②⑥	2
Lin 2007 [62]	30/30	T: 18/12;	T: 54.2;	NSCLC	NP	250 mL, ivgtt, qd, 8d	8d	②④⑤⑥	2
		C: 20/10	C: 57.3
Wang et al. 2007 [30]	28/27	37/12	58.6	NSCLC	NP	250 mL, ivgtt, qd, 21d	21d	①②③④⑤	2
Jiang and Zhuang 2004 [33]	35/32	T: 27/8;	T: 57;	NSCLC	TP	250 mL, ivgtt, qd, 21d	21d	①②③④⑤⑥	2
		C: 26/6	C: 56
Li 2004 [34]	25/15	T: 15/10;	T: 43;	NSCLC	NP	250 mL, ivgtt, qd, 21d	21d	①②④⑤⑥	2
		C: 10/5	C: 45
Zhang et al. 2015 [35]	43/43	T: 28/15;	T: 63.5 ± 6.7;	Colon cancer	XELOX	250 mL, ivgtt, qd, 14d	21d	①②④⑤⑥	2
		C: 29/14	C: 64.3 ± 7.2
Wen et al. 2014 [63]	15/15	T: 12/3;	T: 59.9 ± 7.7;	Gastric cancer	FOLFOX4	250 mL, ivgtt, qd, 10d	14d	①	2
		C: 11/4	C: 59.6 ± 5.6
Yan et al. 2014 [36]	56/56	T: 33/23;	T: 56.2 ± 11.3;	Colon cancer	FOLFOX4	250 mL, ivgtt, qd, 5d	14d	③④⑤⑥	2
		C: 35/21	C: 56.9 ± 10.8
Wen 2014 [37]	23/23	T: 18/5;	66	Gastric cancer	XELOX	250 mL, ivgtt, qd, 10d	21d	①	2
		C: 16/7
Wang 2014 [38]	42/42	T: 23/19;	T: 64.2 ± 11.3;	Gastric cancer	FOLFOX4	250 mL, ivgtt, qd, 14d	28d	①	2
		C: 22/20	C: 65.9 ± 3.4
Han et al. 2014 [39]	34/34	38/30	52.6 ± 4.12	Gastric cancer	FOLFOX6	250 mL, ivgtt, qd, 21d	21d	①③④⑤⑥	2
Wang 2013 [41]	38/38	T: 25/13;	T: 53.6 ± 15.8;	Gastrointestinal cancer	DF	250 mL, ivgtt, qd, 21d	21d	①	2
		C: 24/14	C: 55.3 ± 16.2
Tan et al. 2013 [42]	20/20	28/12	64	Colon cancer	XELOX	250 mL, ivgtt, qd, 14d	21d	①②④⑤⑥	2
Jin 2013 [43]	40/40	T: 24/16;	T: 45.0 ± 12.5;	Gastric cancer	Oxaliplatin & 5-Fu	250 mL, ivgtt, qd, 5d	5d	①②③④⑤⑥	2
		C: 23/17	C: 44.8 ± 12.5
Yin and Jiang 2013 [40]	26/27	T: 14/12;	59	Gastric cancer	SP	250 mL, ivgtt, qd, 24d	21d	①②③④⑤⑥	2
		C: 13/14
Huajun and Xinmei 2012 [45]	28/28	33/23	47.5 ± 3.2	Gastrointestinal cancer	FOLFOX	250 mL, ivgtt, qd, 21d	21d	③④⑤⑥	2
Ren and Wang 2012 [44]	33/32	30/35	62	Gastric cancer	FOLFOX4	250 mL, ivgtt, qd, 14d	14d	①	3
Liu and Han 2011 [46]	45/40	T: 25/20;	T: 64.8 ± 7.0;	Gastric cancer	FOLFOX4	250 mL, ivgtt, qd, 28d	28d	②③④⑤⑥	2
		C: 21/19	C: 65.1 ± 6.9
Guo et al. 2011 [47]	30/24	N	65.4	Colorectal cancer	Oxaliplatin & 5-Fu	250 mL, ivgtt, qd, 7d	14d	①②③④⑥	2
Zhang et al. 2010 [48]	20/20	T: 12/8;	T: 48.5 ± 12.8;	Colorectal cancer	FOLFOX	250 mL, ivgtt, qd, 5d	5d	④	2
		C: 11/9	C: 47.6 ± 11.9
Wang 2010 [50]	30/30	T: 25/5;	T: 58.0 ± 2.9;	Gastrointestinal cancer	Oxaliplatin & 5-Fu	250 mL, ivgtt, qd, 14d	14d	③④⑤⑥	2
		C: 24/6	C: 58.7 ± 2.6
Xu 2010 [49]	30/30	T: 24/6;	57	esophageal cancer	PF	250 mL, ivgtt, qd, 29d	28d	④⑤⑥	2
		C: 26/4
Liang et al. 2009 [54]	76/76	T: 50/26;	53	Colorectal cancer	FOLFOX	250 mL, ivgtt, qd, 10d	21d	①⑥	3
		C: 51/25
Ni et al. 2009 [52]	70/65	T: 44/26;	59	Colorectal cancer	FOLFOX	250 mL, ivgtt, qd, 17d	14d	③④⑤⑥	2
		C: 42/23
Zhang et al. 2009 [51]	40/36	N	56.3	Colon cancer	FOLFOX4	250 mL, ivgtt, qd, 7d	14d	④⑤⑥	2
Liu and Gong 2009 [53]	30/30	38/22	62.5	Gastric cancer	Oxaliplatin & 5-Fu	250 mL, ivgtt, qd, 14d	14d	④⑤⑥	2
Wang et al. 2008 [55]	40/40	T: 22/18;	T: 57.34 ± 16;	Gastrointestinal cancer	FOLFOX6	250 mL, ivgtt, qd, 7d	14d	④⑤⑥	2
		C: 22/18	C: 57.44 ± 16
Sun et al. 2002 [56]	46/32	45/32	49.6	Gastrointestinal cancer	Oxaliplatin & 5-Fu	250 mL, ivgtt, qd, 21d	21d	①③④⑥	2
Wang 2013 [57]	38/38	0/76	T: 45.5 ± 9.8;	Breast cacer	CAF	250 mL, ivgtt, qd, 14d	21d	①	2
			C: 45.2 ± 9.8
Yuan et al. 2008 [59]	38/35	0/73	N	Breast cacer	CAF	250 mL, ivgtt, qd, 20d	20d	②③④⑤⑥	2
Zhu et al. 2008 [58]	32/24	0/56	52.5	Breast cacer	CEF	250 mL, ivgtt, qd, 10d	21d	④⑤⑥	2
Huang et al. 2008 [60]	30/30	0/60	47	Breast cacer	CTF	250 mL, ivgtt, qd, 21d	21d	①③④⑤⑥	3
Dai et al. 2008 [8]	65/65	0/130	T: 45.5 ± 26.8;	Breast cacer	CEF	250 mL, ivgtt, qd, 21d	21d	①②③④⑤⑥	2
			C: 46.1 ± 27.5
Li and Ma 2004 [61]	40/35	0/75	5.46	Breast cacer	NE	250 mL, ivgtt, qd, 10d	28d	①②③④⑤⑥	2

T: the trials where a SQI intervention was conducted; C: the control groups of patients with regular chemotherapy. NSCLC: non-smalll cell lung cancer; SCLC: smalll cell lung cancer; PP: pemetrexed disodium & cisplatine; TP: taxol & cisplatin; NP: navelbine & cisplatin; DP: docetaxel & cisplatin; GP: gemcitabine & cisplatin; XELOX: oxaliplatin and capecitabine; FOLFOX: oxaliplatin, leucovorin calcium and fluorouracil; DF: cisplatin, leucovorin calcium and 5-Fu; SP: cisplatin and fluorouracil derivant; PF: cisplatin and 5-Fu; CAF: cyclophosphamide, adriamycin and fluorouracil; CEF: cyclophosphamide, epirubicin and fluorouracil; CTF: cyclophosphamide, pirarubicin and 5-Fu; NE: navelbine and epirubicin. ^①objective tumor response; ^②natural killer cell (NK)level; ^③matured T lymphocytes () cell level; ^④inducer lymphocyte/helper T lymphocyte () level; ^⑤suppressor T cell/cytotoxic T cell () cell level; ^⑥ ratio.